Publicador de contenidos

Valor de la detección del ARNM de los biomarcadores CDKN2A, MKI67, TOP2A en el diagnóstico precoz de cáncer en hombres que tienen sexo con hombres VIH positivos

Duración
2016 - 2018
Coordinador
Jaume Ordi
Financiadores
Ministerio de Ciencia, Innovación y Universidades. Instituto de Salud Carlos III Unión Europea Este proyecto está cofinanciado por el Fondo Europeo de Desarrollo Regional (FEDER). “Una manera de hacer Europa”

Objective

To evaluate and validate the usefulness of HPV identification followed by mRNA detection of selected biomarkers (CDKN2A, MKi67 and TOP2A) in the screening of anal carcinoma in HIV+ MSM patients.

Design

Observational, prospective, longitudinal study.

Subjects of the study

We will include in the study MSM/VIH+ referred to the Anal Cancer Prevention Unit of the Hospital Clinic/ISGlobal. The following study groups will be included: a) 100 HR-HPV negative patients; b) 100 HR-HPV positive patients with normal cytology; c) 150 HR-HPV positive patients with cytology of ASC or LSIL; d) 150 HR-HPV positive patients with cytology of LSIL; and e) 10 anal carcinomas.

Interventions

Initial recruitment visit with anal cytology. High resolution anoscopy to all patients with abnormal cytology or HR-HPV positive testing. Treatment of patients with HSIL/AIN2-3. One-year follow-up to all patients.

Methodology

  • HPV detection and typing using Xpert HPV (Cepheid);
  • RNA extraction from anal scrapping preserved in liquid based cytology.
  • Identification by RT-PCR of the genotype specific E7 expression in the lesions included.
  • Identification and quantitative analysis of mRNA expression of the genes CDKN2A, MKi67 and TOP2A by quantitative RT-PCR;
  • Immunohistochemical analysis of CDKN2A, MKi67 and TOP2A;
  • Correlation between the biomarker expression and HSIL/AIN2-3.

Total Funding

86.515,00 €

Project Code

PI15/00546

Nuestro equipo

Equipo ISGlobal

Otros proyectos

Ver proyectos pasados

CaDMIA-plus

Validación continuada de la autopsia mínimamente invasiva (MIA) para la investigación de la causa de muerte en niños pequeños, y desarrollo de un centro de investigación y formación sobre el estudio de la causa de muerte

MAMAH

Improving Maternal and Infant Health by reducing malaria risks in African women: evaluation of the safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in HIV-infected pregnant women

ICARIA

Improving Care through Azithromycin Research for Infants in Africa

MIBio

Identification of Prematurity and Pre-Eclampsia as Causes of Mortality

MULTIPLY

MULTIple doses of IPTi Proposal: a Lifesaving high Yield intervention

MA-CoV

Prevalence and impact of SARS-CoV-2 infection on maternal and infant health in African populations

IPERVAC-SL

Impact of perceptions of COVID-19 vaccines on health-seeking behaviours in Sierra Leone

RESPIRE

Respiratory syncytial virus (RSV) in African pregnant women and children

VITAL

Towards preparedness for new maternal vaccinations: Understanding barriers and facilitators to maternal vaccine acceptance

HIV drug resistance (HIVDR)

Description of HIV drug resistance patterns and its association with the risk of HIV mother to child transmission among pregnant women from southern Mozambique

PROTECT

PReparing for Optimal Phase III/IV maTErnal Group B StreptococCal vaccine Trials in Africa